ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2700

Adalimumab Alone Is Superior to Adalimumab Plus Methotrexate in Juvenile Idiopathic Arthritis Associated Uveitis: Data from the ORCHIDEA Registry

Gabriele Simonini1, Fabio Vittadello 2, Francesca Tirelli 3, Maria Elisabetta Zannin 2, Emanuela Del Giudice 4, Claudia Bracaglia 5, Serena Pastore 6, Mariolina Alessio 7, Angelo Ravelli 8, Francesco La Torre 9, Romina Gallizzi 10, Ilaria Maccora 11 and Francesco Zulian 2, 1Rheumatology Unit Anna Meyer Children's Hospital NEUROFARBA Dpt University of Florence, Firenze, Italy, 2Department of Woman and Child Health, University of Padua, Italy, Padova, Italy, 3Post Graduate School of Pediatrics, University of Florence, Florence, Italy, Firenze, Italy, 4Department of Pediatrics, Sapienza University, Rome, Italy, Roma, Italy, 5Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, 6Institute for Maternal and Child Health IRCCS "Burlo Garofolo," Trieste, Italy, Trieste, Italy, 7University Hospital Federico II, Naples, Napoli, Italy, 8IRCCS Istituto Giannina Gaslini, Università degli Studi di Genova, Genova, Italy, 9Rheumatology Unit, Giovanni XXIII Children’s Hospital, Bari, Italy, Bari, Italy, 10Azienda Ospedaliera Universitaria Gaetano Martino, Messina, Messina, Italy, 11Post Graduate School of Pediatrics, University of Florence, Florence, Italy, Florence, Toscana, Italy

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: juvenile idiopathic arthritis (JIA) and anti-TNF therapy, Uveitis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 12, 2019

Title: Pediatric Rheumatology – ePoster III: Systemic JIA, Fever, & Vasculitis

Session Type: Poster Session (Tuesday)

Session Time: 9:00AM-11:00AM

Background/Purpose: To compare the efficacy and safety of Adalimumab alone (ADA) versus ADA in combination with Methotrexate (ADA-MTX) in an open-label, retrospective, comparative, multicentre cohort study of Juvenile Idiopathic Arthritis Uveitis (JIA-U).

Methods: Patients with JIA-U treated with ADA were managed by astandardized protocol and data were entered in the ORCHIDEA registry. At baseline, all patients wererefractory to standard immunosuppressive MTX treatment. Data recordedevery 3 months were uveitis course, number/type of ocular flares and complications, drug-relatedadverse events (AE), and treatment switch or withdrawal. The primary outcome was to assess the time to the first uveitis relapse on ADA treatment, once persistent inactive disease has been achieved. Inactive uveitis was defined as rare or < 1 cell per field at standard slit-lamp examination for at least 3 months. The choice of keeping MTX at 15mg/mq2 with ADA was an opinion-based decision shared between treating ophthalmologist and rheumatologist, at the time of the anti-TNFa start. Data of patients treated for ≥1 year were analyzed.

Results: Up to December 2018, 201 patients (40 Males, median age 4 yrs, range 1-17) with ≥12 months follow-up were enrolled 170 were in the ADA-MTX group, 31 in ADA group. Median age at uveitis onset resulted lower in ADA-MTX group (4 yrs, range 1-17) than ADA (5 yrs, 1-17, Mann-Whitney U test, p< 0.05). No statistical differences between the two groups with regard to age at arthritis onset, number of relapses previous anti TNF treatment, uveitis duration at anti TNF starting and presence of eye complications at base-line have been detected. The overall median time of follow-up without uveitis flares in remission was 24 months (range 1–154). ADA-MTX group showed a shorter relapse-free interval as compared with the ADA group (22 months, range 1-154 vs34 months, range 10-102, Mann-Whitney U test, p= 0.004). Stratifying the two groups by the presence of eye complications at base-line, no significant difference has been noted in 144 JIA-U children without complications. In 57 complicated JIA-U (48 ADA-MTX; 9 ADA), time on remission on treatment resulted shorter in ADA-MTX as compared to ADA (29.2 +24.9 months vs 53.2 +24.5 months, Mann-Whitney U test, p=0.006). Cox regression analysis, at mean of the above-reported covariates, showed a higher probability of maintaining remission on ADA treatment compared to ADA +MTX administration (Mantel-Cox chi-square =19.6, p < 0.001; Figure). The number of pts who experienced drug-related adverse events was not different between the groups: ADA-MTX 44/170 (25.9%) vs ADA 5/31 (16.1%), p: n.s.

Conclusion: JIA-U treating physicians commonly use ADA in combination with MTX. However, according these retrospective data from the ORCHIDEA registry, this approach, even if safe, seems not to provide significant benefits in controlling JIA-U activity over time.


ACR Figure


Disclosure: G. Simonini, None; F. Vittadello, None; F. Tirelli, None; M. Zannin, None; E. Del Giudice, None; C. Bracaglia, None; S. Pastore, None; M. Alessio, None; A. Ravelli, Angelini, AbbVie, Bristol-Myers Squibb, Johnson & Johnson, Novartis, Pfizer, Reckitt Benkiser, and Roche, 2, 5, 8; F. La Torre, None; R. Gallizzi, None; I. Maccora, None; F. Zulian, None.

To cite this abstract in AMA style:

Simonini G, Vittadello F, Tirelli F, Zannin M, Del Giudice E, Bracaglia C, Pastore S, Alessio M, Ravelli A, La Torre F, Gallizzi R, Maccora I, Zulian F. Adalimumab Alone Is Superior to Adalimumab Plus Methotrexate in Juvenile Idiopathic Arthritis Associated Uveitis: Data from the ORCHIDEA Registry [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/adalimumab-alone-is-superior-to-adalimumab-plus-methotrexate-in-juvenile-idiopathic-arthritis-associated-uveitis-data-from-the-orchidea-registry/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/adalimumab-alone-is-superior-to-adalimumab-plus-methotrexate-in-juvenile-idiopathic-arthritis-associated-uveitis-data-from-the-orchidea-registry/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology